Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case study at Dr Batra’s® Homeopathy Clinic, a 15-year-old male with alopecia totalis experienced progressive hair regrowth and emotional well-being improvement over 4-5 months following a classical homeopathic treatment approach, despite previous conventional management.

This case study documented a 36-year-old woman with postpartum-onset frontal fibrosing alopecia who showed significant improvement in hair regrowth after early combination therapy with dutasteride, tofacitinib, and intralesional triamcinolone acetonide, suggesting potential benefits of multimodal treatment in this typically irreversible condition.

In this study, researchers reported that treating alopecia areata patients with ritlecitinib led to progressive improvements in emotional symptoms and activity limitations over 48 weeks, though the post hoc analysis and trial setting suggest caution in interpreting the findings for broader populations.

This study reported significant short-term scalp hair regrowth and increased density in a 4-year-old with Marie Unna hereditary hypotrichosis following topical 5% minoxidil treatment, suggesting its potential benefit in this condition.

This review suggests that melatonin may increase hair density and reduce hair shedding, but variations in study designs highlight the need for more standardized clinical trials.

This case study reported promising hair regrowth in a child with morphea en coup de sabre using fractional CO2 laser-assisted exosome therapy, but further research is needed to validate these findings due to its single-subject design.

This review explores emerging therapies for hair regrowth, highlighting two strategies: hair follicle neogenesis and Wnt/B-catenin pathway modulation, which show promise for treating alopecia by potentially offering more effective options than existing treatments.

Five monthly sessions of minoxidil-dutasteride-copper peptide tattooing significantly improve hair regrowth in men with androgenetic alopecia.

In this study, patients with alopecia areata who experienced sustained hair regrowth while being treated with baricitinib showed improvements in health-related quality of life and reductions in anxiety and depression symptoms over 104 weeks, according to the BRAVE-AA phase III trials.

This study found that a 2-deoxy-D-ribose gel stimulated hair follicle growth in mice with androgenic alopecia, showing effects similar to minoxidil without additional benefits from combining the two treatments.

New microneedle method improves hair regrowth treatment delivery.

In this study, microneedle combined with 5% topical minoxidil significantly increased hair count in androgenetic alopecia, suggesting it as a potential additional therapy option; however, microneedle alone had limited effects.

This study found that treatment with baricitinib 4 mg over 52 weeks led to clinically meaningful regrowth of eyebrows and eyelashes in patients with alopecia areata, even without complete scalp hair regrowth.

Different people with severe hair loss respond to baricitinib treatment at different times, with some showing improvement early, some gradually, and others later.

In this study, researchers identified subgroups of patients with severe alopecia areata treated with baricitinib who experienced early, gradual, or late hair regrowth, finding that response was influenced by baseline disease severity and duration of hair loss.

In this study, researchers reported three cases of alopecia areata patients experiencing a rare targetoid pattern of hair regrowth, a phenomenon originally described in 1988.

This study found that some patients with alopecia areata who did not respond to ritlecitinib treatment by Week 24 achieved a positive response with continued therapy by Week 48, with tolerable side effects.

This study observed that most patients with alopecia areata experienced sustained scalp hair regrowth after 48 weeks of ritlecitinib treatment, with safety consistent with prior findings.

This case study reports significant improvement in severe atopic dermatitis and alopecia areata symptoms in a patient treated with dupilumab, highlighting the potential for patient selection in optimizing therapeutic outcomes.

This promotional content discusses Locerin as a hair growth supplement but reports no research findings; readers are encouraged to explore their own conclusions.

In this study using animal models, microneedle patches loaded with artificial enzymes effectively treated androgenic alopecia, achieving results comparable to the over-the-counter drug minoxidil.

This review explores clinical studies on low-level laser therapy (LLLT) for alopecia and suggests it may benefit patients unresponsive to conventional treatments, but larger studies are needed to confirm efficacy.

New treatment with Wnt proteins and growth factors safely increases hair thickness.

This case report describes a 21-year-old man with alopecia areata presenting as a U-shaped hair loss pattern resembling Hamilton grade VII male-pattern baldness, with no signs of inflammation or related conditions.

In this study, researchers assessed cortisol levels in wolves by comparing hair and fecal samples and found a significant correlation, indicating that hair cortisol accurately reflects systemic levels, but season and body region affect results.

In this study, blue light therapy at a specific wavelength increased hair density and shaft width in 90% of patients with androgenetic alopecia after 10 weeks.

This review examines the definition, classification, mechanism, clinical efficacy for hair regrowth, and potential adverse effects of platelet rich plasma, but does not present new experimental results.

This case report documents two instances of red-haired men with patch-type alopecia areata, where hair regrowth occurred in black rather than red, an unusual phenomenon potentially linked to pigmentation and receptor pathways.

This review discusses current treatments for cicatricial alopecia focused on reducing inflammation to prevent further hair loss and suggests auxiliary therapies to improve the appearance of remaining hair, without reporting new clinical results.